| Item type |
文献 / Documents(1) |
| 公開日 |
2024-07-18 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
関連識別子 |
https://doi.org/10.1111/1759-7714.15115 |
|
|
関連名称 |
10.1111/1759-7714.15115 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non-small cell lung cancer |
| 著者 |
矢葺, 洋平
埴淵, 昌毅
タケウチ, エイジ
ハク, タカシ
兼松, 貴則
ニシムラ, ナオキ
豊田, 優子
三橋, 惇志
大塚, 憲司
佐藤, 正大
後東, 久嗣
米田, 浩人
荻野, 広和
軒原, 浩
篠原, 勉
西岡, 安彦
|
| 抄録 |
|
|
内容記述 |
Background: Although the incidence of lung cancer in elderly individuals has been increasing in recent years, the number of clinical trials designed specifically for elderly patients with advanced non-small cell lung cancer (NSCLC) is still limited. To fulfill this unmet medical need, we conducted a phase II study to elucidate the efficacy of pemetrexed (PEM) plus bevacizumab (Bev) combination chemotherapy in elderly patients with nonsquamous NSCLC.
Methods: A total of 29 elderly patients (≥75 years old) with nonsquamous NSCLC were enrolled in this multicenter, open-label, phase II study, and 27 patients were finally analyzed. PEM at 500 mg/m2 on day 1 plus Bev at 15 mg/kg on day 1 were administered triweekly. The primary endpoint was the investigator-assessed objective response rate.
Results: The median age at initiating chemotherapy was 80 years old. Almost all patients(92.6%) had adenocarcinoma histology. The median number of cycles administered was 6, and the objective response rate was 40.7%. The median progression-free survival, overall survival and 1-year survival were 8.8 months, 27.2 months and 79%, respectively. The treatment was well-tolerated, and no treatment-related death was observed.
Conclusion: Combination chemotherapy with PEM plus Bev in elderly patients with previously untreated advanced non-squamous NSCLC exhibited favorable antitumor activity and tolerability, suggesting that a combination of PEM plus Bev might be a promising treatment option for this population. |
| キーワード |
|
|
主題 |
bevacizumab |
| キーワード |
|
|
主題 |
elderly patients |
| キーワード |
|
|
主題 |
pemetrexed |
| キーワード |
|
|
主題 |
previously untreated nonsquamous non-small cell lung cancer |
| 書誌情報 |
en : Thoracic Cancer
巻 14,
号 32,
p. 3232-3239,
発行日 2023-09-17
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
17597706 |
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
17597714 |
| 出版者 |
|
|
出版者 |
China Lung Oncology Group |
| 出版者 |
|
|
出版者 |
John Wiley & Sons Australia |
| 権利情報 |
|
|
権利情報 |
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| EID |
|
|
識別子 |
405858 |
| 言語 |
|
|
言語 |
eng |
tc_14_32_3232.pdf (714 KB)
.png)
